Correlation of serum calprotectin with outcome of acute cerebral infarction

TL;DR

This study shows that high levels of a protein called calprotectin in the blood can predict poor outcomes in patients with acute cerebral infarction.

Contribution

The study identifies serum calprotectin as a novel independent risk factor for poor outcomes in acute cerebral infarction.

Findings

Elevated serum calprotectin levels are associated with higher stroke severity and worse outcomes in acute cerebral infarction patients.

A cutoff of 18.01 mg/L for serum calprotectin is a strong predictor of poor prognosis in these patients.

Calprotectin levels correlate with NIHSS scores and inversely with GCS scores and hematocrit in ACI patients.

Abstract

This study was to investigate the correlation between serum calprotectin (Cal) and the severity and outcome of patients with acute cerebral infarction (ACI).

Clinical data and serum Cal data were collected from 160 ACI patients and 60 healthy individuals. ACI patients were grouped according to their prognosis. Clinical data, biochemical indicators, and Cal levels were measured. Correlations between serum Cal and National Institute of Health stroke scale (NIHSS) scores, Glasgow Coma Scale (GCS) scores, and hematocrit (HCT) were analyzed.

In ACI patients, elevated serum Cal levels were observed. These levels were positively correlated with NIHSS scores and inversely correlated with GCS scores and HCT. The receiver operating characteristic curve showed that serum Cal had an area under the curve of 0.770 for predicting poor outcomes, with a diagnostic cutoff of 18.01 mg/L. Serum Cal levels over 18.01 mg/L were independently related to poor prognosis for ACI and were identified as an independent risk factor for adverse outcomes.

Serum Cal shows high expression in patients with ACI. Serum Cal has a good predictive value for the outcome of ACI.

Figures